Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab – An attention may be required

Background: C-reactive protein (CRP) is a marker of inflammation and infection. The main proinflammatory cytokine that leads to CRP gene expression is IL-6. The study aimed to compare CRP level between patients who were treated with Tocilizumab (TCZ), an il-6 receptor blocker, and other advanced ant...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mark Berman, Shlomo Berliner, Nancy Bashouti, Ori Elkayam, Tomer Ziv-Baran
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-06-01
Serija:	Heliyon
Teme:	Tocilizumab Infection Rheumatoid arthritis C-Reactive protein Inflammation Admission
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2405844023038720
Oznake:	Označite Brez oznak, prvi označite!